disability

The thickness of two layers of nerve cells forming the back of the eye, or retina, can be used to distinguish patients with progressing forms of multiple sclerosis (MS) from those with stable disease, a study suggests. The study, “Macular ganglion cell–inner plexiform layer…

Treatment with Tysabri (natalizumab) can lessen disability in people with relapsing-remitting multiple sclerosis (RRMS), a large and real-world study found, supporting “confirmed disability improvement” reported in a pivotal clinical trial. Nearly one-quarter of the 5, 384 patients enrolled, particularly those new to treatment, experienced a decrease of at least one…

High levels of neurofilament light chain (NfL) protein circulating in the blood of patients with multiple sclerosis (MS) at an early stage of the disease are linked to higher disability and faster disease progression, a study has found. According to researchers, these findings suggest that NfL — a…

Disability appears to mostly accumulate in people with relapsing forms of multiple sclerosis (MS) in a progressive manner — rather than being due to relapses, a pooled analysis of patients in two Ocrevus (ocrelizumab) clinical trials shows. These findings, indicating that disease progression underlies relapsing MS as well,…

The German Federal Ministry of Education and Research (BMBF) has granted €1.2 million ($1.35 million) to support a project seeking to characterize the function of the protein TRPM4, a potential therapeutic target to prevent nerve cell injury associated with multiple sclerosis (MS), and to develop new drug candidates…

Exposure to disease-modifying therapies does not increase multiple sclerosis (MS) patients’ risk of developing a severe form of COVID-19, according to a registry-based study. However, MS patients who are older, obese, or have severe neurological impairments have a greater risk of developing a severe form of the disease. Findings…

Higher blood levels of the neurofilament light chain (NfL) protein at diagnosis are predictive of worse disability over time in people with multiple sclerosis (MS), a large population study from Sweden suggests. The study, “Plasma neurofilament light levels are associated with the risk of disability in…

Healthcare providers should encourage everyone with multiple sclerosis (MS) to engage in regular exercise and keep physically active, new guidelines based on an expert panel convened by the National Multiple Sclerosis Society recommend. They also suggest different types of exercise applicable to people at varying levels of disability.

People with relapsing multiple sclerosis (MS) being treated with Gilenya (fingolimod) for eight or more years show smaller increases in disability over 10 years than those using this treatment for a shorter time, a long-term follow-up study reports. Longer use of Gilenya also resulted in lesser disability progression,…

Multiple sclerosis (MS) patients who are obese experience a faster degeneration in their optic nerve tissue than those of normal weight, a study found. Since optic neuropathy correlates with greater nerve cell loss in the brain, tracking changes to the retina may be a feasible way to determine…

Starting treatment with Ocrevus early can lower almost by half the need for a walking aid in people with relapsing forms of multiple sclerosis (MS) over six years, new analyses of Phase 3 trial data that compared immediate initiation with a two-year delay show. A separate analysis also found…

People with secondary progressive multiple sclerosis (SPMS) who began treatment with Mayzent early and continued its use for years are less likely to experience disability progression than those starting the medication later in their disease course, five-year data from the EXPAND study suggest. Data from this same Phase 3…

People in Japan with lesions in the cerebral cortex due to multiple sclerosis (MS) were found to have greater cognitive problems, or difficulties thinking, than those without lesions in this area of mostly gray matter that surrounds the brain, a study reports.  Lesions confined to the…

For multiple sclerosis (MS) patients with considerable disability, Ocrevus (ocrelizumab) appears to lower the risk of continued progression in both relapsing and primary progressive forms of the disease, data from an exploratory and post-hoc analysis of three Phase 3 trials report. These findings were in the study, “…

Older age at onset and evidence of active disease, like clinical relapses or inflammatory brain lesions, significantly increase the likelihood of  faster disability progression in primary progressive multiple sclerosis (PPMS), a natural history study suggests. These findings — which included active disease being seen in 31% of the 178…

MedDay Pharmaceuticals‘ MD1003 did not ease functional disability or its progression in patients with non-active progressive multiple sclerosis, Phase 3 clinical trial data shows. The SPI2 Phase 3 study (NCT02936037) sought to confirm the positive results of a first Phase 3 trial called MS-SPI…

An multi-sensor band worn on the arm or leg, called Myo, can capture and relay difficulties with limb movement due to multiple sclerosis (MS) with an accuracy that mirrors gold standard measures of disability, like the Expanded Disability Status Scale (EDSS), a study reports. These findings support the…

Acthar Gel (repository corticotropin injection) leads to significant improvements after two months of use in people with multiple sclerosis (MS) still having acute relapses despite treatment, and who failed to respond to other high-dose corticosteroids, topline data from an observational study show. The gel’s developer, Mallinckrodt Pharmaceuticals, also…

Age, gender, disease subtype, degree of disability, and more factors affect lower urinary tract symptoms (LUTS) among patients with multiple sclerosis (MS). Also, the epidemiology of LUTS must be better understood and promptly detected and treated to improve patients’ quality of life. Those findings are detailed in a new study, “…

The European Commission has approved Novartis‘s Mayzent (siponimod) as the first oral treatment for adults with active secondary progressive multiple sclerosis (SPMS). Active SPMS is defined by the presence of evident relapses or the detection of inflammatory activity in brain lesions on imaging scans. “As the only indicated oral therapy proven for…

Recovering well after a first relapse and starting a disease-modifying therapy (DMT) immediately afterward considerably increases the likelihood of slowing progression in multiple sclerosis (MS), a study suggests. Its findings support relapse recovery as a critical factor for DMT initiation, and one that should be assessed routinely in MS…

A common mutation in the fat-mass obesity (FTO) gene is associated with obesity and increased disability in people with multiple sclerosis (MS), according to a Kuwaiti study. The data, which showed no link between this mutation and an increased risk of MS, highlights the need for more studies about…

Regeneration in the brain is reduced in people with primary progressive multiple sclerosis (PPMS), but enhanced during disease activity in those with relapsing-remitting MS (RRMS), a study reports. The results also show that regeneration is unaffected by treatment with disease-modifying therapies (DMTs), as shown by the levels…

Depression and fatigue have a more powerful influence on the overall health-related quality of life, compared to physical impairment, among patients with multiple sclerosis, a new study shows. The study, “Contributing factors to health‐related quality of life in multiple sclerosis,” was published in the journal Brain and…

A 30-year study of outcomes in multiple sclerosis (MS) patients reports that radiological findings in the first year of disease onset, and the amount of disability evident at five years, helps to predict both the likelihood of a person advancing to secondary progressive MS (SPMS) and long-term survival. The study,…

People with relapsing-remitting multiple sclerosis (RRMS) have poorer neurite density — a measure that relates to the amount of nerve cell projections, including axons and dendrites involved in nerve-to-nerve communication — in the brain and spinal cord than do those without this disease, a study shows. This measure, especially…

Newly launched, the Soothie Cushion is designed to provide seating comfort and help regulate the body temperature of travelers with disabilities, including multiple sclerosis (MS) and myasthenia gravis, says its official retailer, Special Needs Group/Special Needs at Sea (SNG). The product is said to offer enduring comfort…

Interferon therapy (brand names Avonex, Betaseron, and others) is more effective than glatiramer acetate (sold as Copaxone, Glatopa and other generics) for reducing relapses…

Long-term treatment with Gilenya (fingolimod) in patients with relapsing forms of multiple sclerosis (MS) is safe and effective, results from a Phase 3 trial show. Trial findings were reported in the study, “Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results,” published in…

Bladder and bowel problems, such as constipation and fecal incontinence, are associated with a higher level of fatigue in people with multiple sclerosis (MS), according to a study in Australia. The findings also showed that greater fatigue and experiencing bowel and bladder problems are associated with…